2016 American Transplant Congress
Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.
Background:Use of an appropriate immunosuppressant is necessary for good graft survival in kidney transplantation (KTx). Currently, a prolonged-release formulation of tacrolimus (Graceptor or Adovagraf, Astellas…2016 American Transplant Congress
After Alemtuzumab Induction, Tac+MMF Is Superior to CsA+MMF in Pediatric Kidney Transplantation.
1Boris Petrovsky SCS, Moscow, Russian Federation; 2Mount Sinai Hospital, New York, NY.
Introduction: Recipient parenchymal lymphatic cells are crucial for direct and indirect pathways of allorecognition. We proposed that administering alemtuzumab several weeks pretransplantation could eradicate peripheral…2016 American Transplant Congress
Outcomes in Elderly Renal Transplant Recipients Using Thymoglobulin or Interleukin-2 Receptor Antagonist Induction.
1Pharmacy, University of Illinois, Chicago; 2Transplant Surgery, University of Illinois, Chicago.
Background: Approximately 20% of all renal transplants performed in the US in 2014 occurred in elderly patients. Elderly patients are known to be at higher…2016 American Transplant Congress
Induction with T-cell Depletional Agents Is Safe and Efficacious in the Very Elderly Kidney Transplant Recipients: An Analysis of the OPTN Database.
Virginia Commonwealth University, Richmond, VA.
Background: Kidney transplantation is increasingly being offered to the very elderly (Age>70 years) kidney transplant recipients. Previous studies analyzing the effect of induction immunosuppression in…2016 American Transplant Congress
Comparison of De Novo Donor Specific Antibody Formation for Kidney Transplant Recipients Induced with Thymoglobulin or Basiliximab.
Division of Transplantation, University of Southern California, Los Angeles, CA.
Background: Thymoglobulin (ATG) and basiliximab (Bas) induction are commonly used therapies to prevent allograft rejection in kidney transplant recipients (KTx). Formation of donor specific antibodies…2016 American Transplant Congress
Reduced CMV Infection Using Single Low-Dose of Rabbit Anti-Thymocyte Globulin in Kidney Transplanted Recipients.
Hospital do Rim - UNIFESP, Sao Paulo, Brazil.
BACKGROUND: Cytomegalovirus (CMV) infection is associated with significant morbidity and mortality after solid organ transplantation and the historic incidence of our institution was 77%. Aiming…2016 American Transplant Congress
Quality Assessment and Process Improvement of Thymoglobulin Dosing.
University of Minnesota, Minneapolis.
Thymoglobulin (Thymo) induction is given to prevent early rejection while initiating maintenance immunosuppression. Modification of dosing is common for multiple reasons. Our center recently underwent…2016 American Transplant Congress
Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.
Transplantation, The University of Toledo, Toledo, OH.
Background: The highly successful induction drug Alemtuzumab (Campath) is commonly used prior to renal transplant. Yet, it does not completely ablate plasma cell which, in…2016 American Transplant Congress
Safety, Efficacy, and Cost Saving Potential of Various Weight-Based Dosing for Thymoglobulin Induction Therapy in Kidney Transplant Recipients.
Introduction: There are limited data assessing the appropriate weight to use when dosing Thymoglobulin for induction therapy. The aim of this study is to assess…2016 American Transplant Congress
Induction Agent Use and Outcomes in Older KT Recipients: Patient and Center Level Associations.
Background: Clinical trials of induction agents typically exclude older recipients, so our practice in older recipients is extrapolated from this. Older adults are different, so…
American Transplant Congress abstracts